Project Name:Erlotinib
Registration Classification:3+6
Formulations and specifications :Tablets: 25mg, 100mg, 150mg
Indications:For locally advanced or metastatic non-small cell lung cancer (NSCLC) after at least one previously failure chemotherapy .
Original Research Company:Roche
Progress :Pharmaceutical Research in progress
地址:北京市丰台区造甲街南里5号4A楼2层 电话:010-63716441 63717341 传真:010-63728443 COPYRIGHT (C) 2014 Beijing Mega Pharmaceutical Science and Technology Co.,ltd. ALL RIGHTS RESERVED 版权所有 北京满格医药科技有限公司 京ICP备12000952号